
Exagen Inc (XGN) Stock Forecast & Price Target
Exagen Inc (XGN) Analyst Ratings
Bulls say
Exagen Inc. has demonstrated significant growth potential, evidenced by a year-to-date share increase of 133%, marking it as a frontrunner in the diagnostics sector. The company reported a 19% year-over-year revenue growth for the first nine months, supported by a balanced 9% increase in average selling prices (ASPs) and an 8% rise in testing volumes. Additionally, Exagen’s Q3 performance reflected a remarkable 38% year-over-year revenue growth, bolstered by improvements in both volume and pricing, positioning the company favorably for future expansion within the market.
Bears say
Exagen Inc. has faced a negative outlook due to a significantly lowered growth forecast for 2026, alongside delays in achieving positive free cash flow. This revision is compounded by reduced revenue growth estimates and diminished expectations for average selling price (ASP) and gross margin expansion in the near term. Additionally, the company has shown a notable decline in its stock value, with shares dropping more than 60% following its third-quarter 2025 results, raising concerns among investors about growth prospects and profitability.
This aggregate rating is based on analysts' research of Exagen Inc and is not a guaranteed prediction by Public.com or investment advice.
Exagen Inc (XGN) Analyst Forecast & Price Prediction
Start investing in Exagen Inc (XGN)
Order type
Buy in
Order amount
Est. shares
0 shares